Research ArticleCancer

Targeted BMI1 inhibition impairs tumor growth in lung adenocarcinomas with low CEBPα expression

See allHide authors and affiliations

Science Translational Medicine  03 Aug 2016:
Vol. 8, Issue 350, pp. 350ra104
DOI: 10.1126/scitranslmed.aad6066

The right drug for the right tumor

The expression of a tumor suppressor called C/EBPα is often lost in non–small cell lung cancer, as well as in other cancer types. Yong et al. discovered that lung tumors deficient in C/EBPα often overexpress a particular oncogenic protein, BMI1, and that higher expression of BMI1 correlates with worse prognosis in this group of patients. The authors characterized the role of these two proteins and their interaction in lung cancer development, then used cell lines and a genetic mouse model to test a therapeutic approach, showing that a pharmaceutical inhibitor of BMI1 is effective against non–small cell lung cancer with low C/EBPα and high BMI1.

View Full Text

Stay Connected to Science Translational Medicine